烟台东诚药业集团股份有限公司 第六届董事会第三次独立董事专门会议 一、独立董事专门会议召开情况 2025 年 4 月 29 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 召开了第六届董事会第三次独立董事专门会议。会议通知于 2025 年 4 月 25 日以 通讯方式送达，会议应出席独立董事 2 人，实际出席独立董事 2 人，会议的召集、 召开和表决程序符合《公司章程》、《上市公司独立董事管理办法》、《独立董事工 作制度》等规定。 二、会议审议情况 全体独立董事经过审议，审议通过了如下议案： 一、《关于购买控股子公司少数股东股权暨关联交易的议案》 经审核，我们认为：公司本次购买景林景盈所持有的蓝纳成的股份事项，交 易价格根据《增资协议》、《股东协议》及交易各方共同协商确定，不存在损害公 司及公司股东利益的情形。 表决结果：同意 2 票，反对 0 票，弃权 0 票。 独立董事：李方、赵大勇 2025 年 4 月 29 日 ...

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [1]. Core Insights - The commercialization of nuclear medicine is accelerating, with significant growth in diagnostic nuclear drugs and the potential for domestic nuclear drugs to reach a commercialization inflection point [3][17]. - The report highlights the successful commercialization of Pluvicto and Lutathera, which are expected to generate substantial revenues, with Pluvicto projected to exceed $5 billion in peak sales [3][12]. - The report emphasizes the similarities between Radioligand Therapy (RDC) and Antibody-Drug Conjugates (ADC), suggesting that RDC could replicate the success of ADC in the market [3][22]. Summary by Sections Part 1: Overseas Nuclear Drug Rapid Growth, Domestic Commercialization Period - Overseas nuclear drugs are experiencing rapid commercialization, with Pluvicto achieving $1.392 billion in revenue in 2024, a 42% increase, and Lutathera generating $724 million, a 20% increase [3][12]. - The combined revenue from these two drugs for Novartis reached $2.116 billion, indicating the ongoing value realization of nuclear drugs [3][12]. - The report notes that the domestic nuclear drug market is set to expand significantly, with five new nuclear drugs approved since 2020, including Yttrium-90 microspheres from Yuan Da Pharmaceutical, which is expected to generate nearly HKD 500 million in revenue in 2024, a growth rate exceeding 140% [3][20]. Part 2: RDC Expected to Replicate ADC Success Path - RDC shares structural and mechanistic similarities with ADC, consisting of a targeting ligand, a linker, and a radioactive nuclide [3][22]. - The report outlines that both RDC and ADC have followed similar validation timelines, with ADC gaining market traction after the success of Enhertu, while RDC is now gaining attention following the success of Pluvicto [3][22]. - The market for new nuclear drugs is projected to reach approximately $4-5 billion in 2024, comparable to the ADC market size around 2021 [3][22]. Part 3: Domestic Nuclear Drug Pipeline Overview - The report details the current pipeline of domestic nuclear drugs, with three products in the NDA stage, including Novartis's PSMA diagnostic and therapeutic drugs [3][49]. - The leading targets in domestic research remain PSMA, FAP, and SSTR, with companies like Yuan Da Pharmaceutical and Xiantong Pharmaceutical leading in clinical project numbers [3][53]. - The anticipated approval of Novartis's two PSMA-targeted products in Q2 2025 is expected to further stimulate the domestic nuclear medicine market [3][20].

Group 1 - The core viewpoint of the article highlights the significant presence of large private equity firms in the A-share market, with 21 private equity firms holding shares in 51 A-share companies, totaling a market value of 20.2 billion yuan as of April 14 [2] - In the fourth quarter, 16 new stocks were added by private equity firms, 7 stocks were increased, 17 stocks remained unchanged, and 11 stocks were reduced [2] - The distribution of heavy holdings by private equity firms shows that the basic chemical industry had the highest number of stocks at 10, followed by the electronics industry with 9, and both machinery equipment and pharmaceutical biology industries with 6 each [2] Group 2 - Gao Yi Asset held 11 stocks in the fourth quarter, with a total market value of 10.194 billion yuan, including a new investment in Yangnong Chemical of 3.932 million shares valued at 2.275 billion yuan [2] - Gao Yi Asset increased its holdings in Tong Ren Tang, Zhongju High-tech, Zijin Mining, and Ruifeng New Materials, with respective increases of 8.5 million shares, 7.7 million shares, 7.2151 million shares, and 1 million shares, valued at 954 million yuan, 694 million yuan, 5.169 billion yuan, and 619 million yuan [2] - Gao Yi Asset maintained its holdings in Shengyi Technology and Tiandi Technology, with market values of 1.203 billion yuan and 104 million yuan respectively, while reducing its holdings in Yuntianhua, Angel Yeast, Dongcheng Pharmaceutical, and Health元 by 942,400 shares, 10 million shares, 1 million shares, and 1,854,640 shares respectively [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The pharmaceutical sector shows higher certainty under the backdrop of the tariff war, with a focus on innovation and domestic substitution strategies [1][15] - The A-share pharmaceutical index has increased by 1.20% this week and 4.77% year-to-date, outperforming the CSI 300 by 2.57% and 6.64% respectively [3][9] - The report highlights the approval of significant drugs in China, such as Roche's Ocrelizumab for multiple sclerosis and Novartis' Pluvicto for prostate cancer treatment [3][4] Summary by Sections Industry Performance - The A-share pharmaceutical index has shown a weekly increase of 1.20% and a year-to-date increase of 4.77%, while the H-share biotech index has increased by 1.7% this week and 30.77% year-to-date [3][9] - Notable stock performances include Duorui Pharmaceutical (+56%), Oukang Pharmaceutical (+49%), and Weisi Medical (+31%) [3][9] Tariff Impact - The recent U.S. tariff exemptions for the pharmaceutical industry include drug formulations, active pharmaceutical ingredients, and plant extracts, indicating minimal impact on the sector [3][15] - The report notes that 90% of antiviral and antibiotic drugs consumed in the U.S. rely on imported active pharmaceutical ingredients, with a significant portion coming from India and China [15][16] Investment Strategy - Recommended investment focus areas include innovative drugs, blood products, research services, and medical devices, with a specific emphasis on domestic companies benefiting from tariff changes [10][16] - Companies to watch include Baijia Shenzhou, Kelun Pharmaceutical, and Shanghai Laisai in the innovative drug sector, and Shanghai Laisai and Boya Biological in blood products [10][16] R&D Developments - Over 200 Chinese innovative drugs are set to be showcased at the 2025 AACR conference, reflecting the growing international recognition of domestic innovations [3][18] - The report lists several key drugs and their respective companies that have received U.S. approvals, highlighting the advancements in the Chinese pharmaceutical sector [18][19]

证券代码：002675 证券简称：东诚药业 公告编号：2025-020 烟台东诚药业集团股份有限公司 2024 年度股东大会决议公告 一、会议召开情况 （一）召开时间： 现场会议时间：2025年3月28日（星期五）14:30； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年3月28日9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025年3月28日9:15-15:00期间的任意时间。 （二）现场会议地点：烟台经济技术开发区长白山路7号公司会议室； （六）本次股东大会的召集、召开程序符合《公司法》《上市公司股东大会 规则》等法律、法规、规范性文件和《公司章程》的规定。 二、会议出席情况 参加本次会议的股东及股东代理人共133人，代表公司有表决权的股份 237,307,781股，占公司有表决权股份总数的28.7787%。其中：1、出席本次现场 会议的股东及股东代表共3人，代表有表决权的股份数231,250,495股，占公司有 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或 ...

北京市中伦律师事务所 关于烟台东诚药业集团股份有限公司 2024 年度股东大会的 法律意见书 致：烟台东诚药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等规定， 北京市中伦律师事务所（以下简称本所）接受烟台东诚药业集团股份有限公司（以 下简称公司）的委托，指派本所律师对公司 2024 年度股东大会（以下简称本次 股东大会）进行见证并就相关事项出具本法律意见书。 为出具本法律意见书，本所律师查阅了公司提供的相关文件，包括但不限于： 1. 现行《烟台东诚药业集团股份有限公司章程》（以下简称《公司章程》）； 2. 公司于 2025 年 2 月 27 日刊登在深圳证券交易所网站（www.szse.cn）、 巨潮资讯网（www.cninfo.com.cn）的第六届董事会第九次会议决议公告、关于召 开本次股东大会的通知； 3. 公司本次股东大会股权登记日（2025 年 3 月 24 日）的股东名册、出席现 场会议的股东的到会登记记录及凭证资料； 4. 公司本次股东大会的会议文件。 1 法律意见书 在本法律意见书中， ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company reported a revenue of 2.869 billion yuan in 2024, a year-on-year decrease of 12.42%, and a net profit attributable to shareholders of 184 million yuan, also down 12.35% year-on-year. The adjusted net profit decreased significantly by 62.69% to 79 million yuan. However, in the fourth quarter, the company achieved a revenue of 707 million yuan, a year-on-year increase of 2.35%, and a net profit of 17 million yuan, marking a turnaround from losses [5][14] Summary by Sections Business Performance - The company's raw material drug business saw a revenue of 1.255 billion yuan in 2024, down 25.17% year-on-year, primarily due to a decline in the sales price of heparin sodium. The demand for heparin raw materials is improving, although the export price has been affected by raw material costs. The nuclear medicine business remained stable, with revenues from 18F-FDG at 421 million yuan (up 0.25% year-on-year) and from cloud injection solutions at 231 million yuan (down 5.48% year-on-year) [15] Nuclear Medicine Development - The company has a leading position in nuclear medicine facilities and product layout. It has received approval for the launch of technetium-99m labeled drugs and has several products in the III phase of clinical trials. The company operates multiple nuclear medicine centers, covering 93.5% of the domestic population's nuclear medicine needs [16] Future Projections - The company is expected to see revenues of 3.098 billion yuan, 3.361 billion yuan, and 3.661 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 7.99%, 8.50%, and 8.93%. The net profit attributable to shareholders is projected to be 237 million yuan, 264 million yuan, and 297 million yuan for the same years, with growth rates of 28.97%, 11.54%, and 12.23% respectively. The earnings per share (EPS) are expected to be 0.29 yuan, 0.32 yuan, and 0.36 yuan [17]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's short-term performance is impacted by increased costs, but the innovative nuclear medicine research is progressing steadily [5][7] - In 2024, the company achieved a revenue of 2.869 billion yuan, a decrease of 12.42%, and a net profit attributable to shareholders of 184 million yuan, down 12.35% [7] - The company anticipates marginal improvement in 2025 as the demand for heparin raw materials gradually recovers [7] Financial Summary - The latest closing price is 13.25 yuan, with a one-year high of 16.29 yuan and a low of 11.28 yuan [3] - The current P/E ratio is 59.44, and the P/B ratio is 2.44 [3] - The total share capital is 8.25 billion shares, with a total market value of 10.926 billion yuan [3] Profit Forecast - Revenue projections for 2025 to 2027 are 3.141 billion yuan, 3.433 billion yuan, and 3.737 billion yuan, with growth rates of 9.5%, 9.3%, and 8.9% respectively [6] - Net profit attributable to shareholders is expected to be 235 million yuan, 286 million yuan, and 339 million yuan for the same years, with growth rates of 28.1%, 21.2%, and 18.8% respectively [6] - The estimated P/E ratios for 2025, 2026, and 2027 are 46.4, 38.3, and 32.2 respectively [6]

Investment Rating - The report assigns an initial "Buy" rating for the company [1]. Core Views - The company is entering a harvest period for its nuclear medicine platform, with stable revenue contributions expected from its core heparin business starting in 2025 [7]. - The nuclear medicine industry is experiencing demand expansion, with a stable duopoly supply structure, and the company is well-positioned to benefit from this growth [7]. - The company has a comprehensive supply network in the nuclear medicine sector, which enhances its competitive advantage compared to international peers [7]. - The company’s innovative nuclear medicine pipeline is expected to yield commercial returns in the near future, with several products in advanced clinical stages [7]. - The financial forecast indicates a recovery in revenue and profit from 2025 onwards, driven by the commercialization of new nuclear medicine products [7]. Summary by Sections 1. Company Overview - The company is a leading innovator in nuclear medicine research and production, with a comprehensive business model covering raw materials, formulations, nuclear medicine, and health products [14]. 2. Nuclear Medicine Industry - The nuclear medicine market is characterized by high entry barriers and strong growth potential, primarily used for imaging diagnostics and tumor treatment [31]. - The global nuclear medicine market is projected to grow at a CAGR of 11.5% from 2024 to 2033, with significant opportunities in China, where the market is expected to grow at a CAGR of 32.4% from 2021 to 2025 [7]. 3. Company’s Nuclear Medicine Pipeline - The company has a robust pipeline of nuclear medicine products, with several candidates in late-stage clinical trials, including treatments for prostate cancer and other malignancies [7]. - The company’s nuclear medicine segment achieved revenue of 1.01 billion yuan in 2024, with a gross margin of 69.1%, indicating strong profitability in this area [22]. 4. Financial Projections - Revenue projections for 2025-2027 are 32.2 billion yuan, 37.1 billion yuan, and 41.9 billion yuan, respectively, with corresponding net profits of 2.2 billion yuan, 3.2 billion yuan, and 4.0 billion yuan [7]. - The current P/E ratios for the company are projected to be 50, 34, and 27 for the years 2025, 2026, and 2027, respectively, suggesting potential undervaluation given the expected growth [7].